• This ESMO Clinical Practice Guideline update addresses new developments in the management of biliary tract cancer. • Recommendations are given for first-line treatment with immune checkpoint inhibitors. • Key recommendations are also provided for second-line treatment with targeted therapies. • The update also covers the latest developments in molecular testing and intra-arterial therapies. • A management algorithm for early-stage, locally advanced and advanced/metastatic disease is provided.
No takes yet. Share an insight, caveat, or question.
Vogel et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: